PsyBio’s Objective Is to Develop Ground-Breaking Patient Treatments Based Upon Psychedelic Agents
PsyBio Therapeutics is creating a portfolio of unique, scientifically developed, psychoactive compounds as potential therapeutic agents for mental and neurologic health issues and developing an efficient, patent-pending bacterial biosynthesis process for tryptamine production with platform technology utilizing metabolic engineering and optimization techniques.
Research & Development Partners
Miami University, Oxford, OH
Noble Capital Markets